Skip to NavigationSkip to content


NICE chair: pharma must show how it prices drugs

Haslam image
Professor David Haslam (Credit: Financial Times Live)

The pharmaceutical industry must be willing to show the public how it prices its drugs - or face losing its trust.

This is according to the chairman of NICE Professor David Haslam, who tells Pharmafile that currently no one outside the boardroom of a pharma firm knows how it evaluates a drug’s worth.

“If we could have greater transparency about pricing, then a lot of problems could be bypassed - it’s not just that drugs are expensive and NICE says no, it’s about the cost-effectiveness of
these medicines. 

NICE launches VBA consultation

NICE image

NICE has today launched its consultation into how value-based assessment of drugs will work in practice, which will run for the next three months until 20 June.

This is part of the renewed PPRS scheme, the new drug pricing policy for the UK, which came into force in January and was set to be a value-based pricing system, but has been downgraded to ‘value-based assessment’ (VBA).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches